Literature DB >> 1651593

Adeno-associated viruses having nonsense mutations in the capsid genes: growth in mammalian cells containing an inducible amber suppressor.

J W Smuda1, B J Carter.   

Abstract

When an adeno-associated virus (AAV) genome contained in a recombinant plasmid is transfected into adenovirus-infected cells, infectious AAV particles are efficiently generated. We previously described the construction of a conditional lethal mutant of AAV having an amber termination codon inserted in the rep gene. This mutant was propagated on a monkey kidney cell line (SupD12) having an inducible amber suppressor tRNAser. We now describe the construction and propagation of two additional conditional lethal mutants of AAV having amber codons affecting all three capsid proteins (AAV Capam) or only the VP1 capsid protein (AAV VP1am). Suppression of the amber mutations in the capsid proteins was demonstrated directly by immunoblot analysis. The efficiency of amber suppression on the SupD12 cell was about 6 to 10% for AAV VP1am and 4 to 5% for AAV Capam. The reversion frequency of either mutant was apparently less than 10(-5). On nonsuppressing cells AAV VP1am exhibited an Lip (Inf) phenotype, whereas AAV Capam exhibited a Cap phenotype.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1651593     DOI: 10.1016/0042-6822(91)90847-5

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  Adeno-associated viruses undergo substantial evolution in primates during natural infections.

Authors:  Guangping Gao; Mauricio R Alvira; Suryanarayan Somanathan; You Lu; Luk H Vandenberghe; John J Rux; Roberto Calcedo; Julio Sanmiguel; Zahra Abbas; James M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-25       Impact factor: 11.205

2.  Cloning of an avian adeno-associated virus (AAAV) and generation of recombinant AAAV particles.

Authors:  Ioannis Bossis; John A Chiorini
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

3.  Site-directed mutagenesis of adeno-associated virus type 2 structural protein initiation codons: effects on regulation of synthesis and biological activity.

Authors:  S Muralidhar; S P Becerra; J A Rose
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

4.  Nuclear transport of the major capsid protein is essential for adeno-associated virus capsid formation.

Authors:  M Hoque; K Ishizu; A Matsumoto; S I Han; F Arisaka; M Takayama; K Suzuki; K Kato; T Kanda; H Watanabe; H Handa
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

5.  Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection.

Authors:  C E Wobus; B Hügle-Dörr; A Girod; G Petersen; M Hallek; J A Kleinschmidt
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

6.  Assembly of viruslike particles by recombinant structural proteins of adeno-associated virus type 2 in insect cells.

Authors:  M Ruffing; H Zentgraf; J A Kleinschmidt
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

7.  Intermediates of adeno-associated virus type 2 assembly: identification of soluble complexes containing Rep and Cap proteins.

Authors:  A Wistuba; S Weger; A Kern; J A Kleinschmidt
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

8.  Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus.

Authors:  Kenneth H Warrington; Oleg S Gorbatyuk; Jeffrey K Harrison; Shaun R Opie; Sergei Zolotukhin; Nicholas Muzyczka
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

9.  Naturally occurring singleton residues in AAV capsid impact vector performance and illustrate structural constraints.

Authors:  L H Vandenberghe; E Breous; H-J Nam; G Gao; R Xiao; A Sandhu; J Johnston; Z Debyser; M Agbandje-McKenna; J M Wilson
Journal:  Gene Ther       Date:  2009-12       Impact factor: 5.250

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.